CureVac에 대한 매도 수량은 투자자에게 CureVac의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

CureVac (NASDAQ:CVAC) 주식, 공매도 수량 보고

CureVac

CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.

Large Cap

News

Health Care

General

CVAC

MRNA

NVAX

네바다의 한 낙농업자가 1월에 루이지애나 남자의 사망과 관련된 조류 독감 D1.1 변종에 양성 반응을 보였다고 CNN이 보도했다. 미국 질병통제예방센터(CDC)는 월요일에 초기 양성 반응을 확인하기 위해 작업 중이다.

네바다 남성에서 발견된 치명적인 조류 독감 변종: 주목해야 할 4가지 주식

CureVac NV

Macro Economic Events

Econ #s

Economics

USA Core PPI (MoM) For Jan. 0.3% Vs 0.3% Est.; 0.4% Prior

Market-Moving Exclusives

Exclusives

WAVE

EXCLUSIVE: Eco Wave Power Tells Benzinga 'The collaboration aligns with India's Ministry of New and Renewable Energy's (MNRE) recognition of ocean energy as a promising renewable resource, with an estimated 40,000 MW of untapped potential'

EXCLUSIVE: Eco Wave Power Tells Benzinga Co. And Fortune 500 Bharat Petroleum To Tap Into India's 40,000 MW Wave Energy Potential With Landmark MoU

Macro Notification

US PPI (Month Over Month) For Jan. : +0.4% vs +0.3% Est.

Barclays analyst Andrew Mok maintains Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) with a Overweight and lowers the price target from $190 to $161.

Price Target

Analyst Ratings

Barclays Maintains Overweight on Tenet Healthcare, Lowers Price Target to $161

Sadot Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDOT#NASDAQ">SDOT</a>) ("Sadot Group" or the "Company") today announced the appointment of Ms. Catia Jorge as its new Chief Executive Officer, effective immediately. Ms. Jorge, a seasoned leader in the global agri-commodity sector, joins Sadot Group at a pivotal time, as the Company transitions to focusing on expanding its platform globally. Ms. Jorge will report to the Board of Directors and lead Sadot's strategic initiatives, global operations, and business growth efforts to maximize the Company's long-term potential.
A highly regarded industry veteran, Ms. Jorge brings nearly 30 years of experience in agricultural markets, commodity trading, and operational leadership. She most recently served as Brazil Country Head and Vice President/Grains Business Head Latin America for Olam Agri, where she managed a $1.0 billion annual revenue portfolio. Prior to Olam, she held leadership roles at Cargill Agricola South America exporting over 7 million metric tons of grain exports annually as well as leadership positions at J. Macedo. Ms. Jorge has a proven track record of scaling global agricultural businesses and driving operational excellence.

Management

SDOT

Sadot Group Appoints Catia Jorge As New Chief Executive Officer

Needham analyst John Todaro maintains Robinhood Markets (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) with a Buy and raises the price target from $52 to $70.

HOOD

Needham Maintains Buy on Robinhood Markets, Raises Price Target to $70

Sonnet BioTherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) reported quarterly losses of $(1.56) per share which missed the analyst consensus estimate of $(1.39) by 12.23 percent. This is a 36.59 percent increase over losses of $(2.46) per share from the same period last year.

Earnings

Earnings Misses

SONN

Sonnet BioTherapeutics Q1 EPS $(1.56) Misses $(1.39) Estimate

Guidance

GAME

GameSquare Expects Revenue From World Building Campaigns To Grow 100% Year-Over-Year To ~$8M

Glimpse Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRAR#NASDAQ">VRAR</a>) reported quarterly sales of $3.17 million which beat the analyst consensus estimate of $3.10 million by 2.22 percent. This is a 52.65 percent increase over sales of $2.08 million the same period last year.

Earnings Beats

VRAR

Glimpse Group Q2 Sales $3.17M Beat $3.10M Estimate

Susquehanna analyst Shyam Patil maintains Zillow Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZG#NASDAQ">ZG</a>) with a Neutral and raises the price target from $75 to $80.

Susquehanna Maintains Neutral on Zillow Gr, Raises Price Target to $80

Barclays analyst Alex Scott maintains Sun Life Financial (TSX:<a class="ticker" href="https://www.benzinga.com/stock/SLF#TSX">SLF</a>) with a Equal-Weight and lowers the price target from C$87 to C$85.

TSX:SLF

Barclays Maintains Equal-Weight on Sun Life Financial, Lowers Price Target to C$85

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2025/02/12/final-trades-vertiv-holdings-spotify-and-the-iyh.html">Halftime Report Final Trade</a>s,&#8221; Joseph M. Terranova of Virtus Investment Partners picked Spotify Technology S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>).
Spotify, on Feb. 4, reported better-than-expected fiscal fourth-quarter 2024 financial sales. 
The Stockholm-based company reported quarterly sales of $4.53 billion (4.24 billion euros), up by 16% year-on-year, which beat the analyst consensus estimate of $4.15 billion.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>.
Stephen Weiss of Short Hills Capital Partners said he is sticking with Vertiv Holdings Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>) as the stock got cheaper on Wednesday. &#8220;It's a good opportunity to <a href="https://in.benzinga.com/25/02/43661891/vertiv-q4-results-highlight-robust-data-center-demand-shares-down-on-q1-guidance">get in,&#8221; he added.</a>
Shares of Vertiv dipped around 10% on Wednesday following results for its fourth quarter. Net sales rose 26% year-over-year to $2.346 billion, beating the consensus of $2.151 billion. 
For 2025, Vertiv said it sees revenue of $9.125 billion – $9.275 billion vs. consensus of $9.148 billion and adjusted EPS of $3.50 – $3.60 vs. consensus of $3.56. For the first quarter, Vertiv expects revenue of $1.900 billion- $1.950 billion (vs. $1.904 billion estimate) and adjusted EPS of $0.57 – $0.63 <a href="https://www.benzinga.com/calendars/guidance">(vs. consensus of $0.64)</a>.
Shannon Saccocia of NB Private Wealth named iShares U.S. Healthcare ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IYH#NYSE">IYH</a>) as her final trade.
Price Action:
<ul>
<li>Vertiv shares declined 9.7% to close at $111.24 on Wednesday.</li>
<li>iShares U.S. Healthcare ETF slipped 0.2% during Wednesday's session.</li>
<li>Spotify shares gained 2.8% to close at $640.59 on Wednesday.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43656665/wall-streets-most-accurate-analysts-weigh-in-on-3-tech-telecom-stocks-with-over-3-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Tech &amp; Telecom Stocks With Over 3% Dividend Yields</a></li>
</ul>
Image: Shutterstock

Long Ideas

Markets

Media

Trading Ideas

iShares Trust Dow Jones US Healthcare Sector Index Fund

SPOT

Spotify, Vertiv Holdings And More: CNBC's 'Final Trades'

Webuy Global Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBUY#NASDAQ">WBUY</a>) ("Webuy" or the "Company"), a leading AI-driven e-commerce and travel platform, today provided an update regarding its Nasdaq listing status and ongoing strategic growth initiatives.
 Nasdaq Compliance and Appeal Process On January 22, 2025, Webuy received a delisting notice from Nasdaq due to non-compliance with the $1.00 minimum bid price requirement. Following the expiration of the second 180-day compliance period on January 21, 2025, Nasdaq suspended trading of the Company's stock on January 31, 2025. As a result, Webuy's shares are currently trading on the OTC market due to the implementation of new Nasdaq regulations that mandate immediate delisting after the second compliance period.
 To regain its Nasdaq listing, the Company has formally appealed the decision and is scheduled to present its compliance plan at a hearing on February 27, 2025.
 Reverse Stock Split and Compliance Plan To address the bid price deficiency, Webuy's shareholders approved a reverse stock split at the Company's Annual General Meeting (AGM) on December 18, 2024, with an approved ratio ranging from 1-for-10 to 1-for-40. On January 15, 2025, the Board of Directors approved a 1-for-40 reverse stock split, and the Company immediately filed the required documents with the secretary of Cayman Islands on January 16, 2025.
 Following the delisting notice, the Company's shares are now on the OTC market, under which additional approval from the Financial Industry Regulatory Authority (FINRA) is required to proceed with the reverse split. Webuy submitted its FINRA application on February 3, 2025 and has been actively responding to FINRA to provide supplemental information as requested, and is expecting FINRA clearance in due course.
 Strong Business Performance and AI Expansion Despite the above procedural challenges, Webuy remains financially robust and is actively expanding its AI-driven business model to drive growth. On December 17, 2024, the Company successfully raised $3.6 million in a registered direct offering, which would be used to enhance its AI-powered solutions across e-commerce and travel, including: • &nbsp; &nbsp;Enhancing the AI-powered Travel Consultant for personalized itinerary planning. • &nbsp; &nbsp;Improving predictive demand analytics to optimize the group-buy model. • &nbsp; &nbsp;Strengthening community engagement through AI-driven tools.
 Commitment to Shareholders Webuy remains committed to regaining its Nasdaq listing and executing its AI-driven growth strategy to create long-term shareholder value. The Company will continue to update shareholders on its progress and remain dedicated to delivering innovative solutions that enhance customer experiences.

WBUY

Webuy Global Provides Nasdaq Listing Update Amid Delisting; Appeals In Process; Implements 1-For-40 Reverse Stock Split Pending FINRA Clearance; Reports Strong AI-Driven Business Performance; Raised $3.6M For E-Commerce And Travel Expansion

Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) is reportedly exploring the development of&nbsp;humanoid and non-humanoid robots for&nbsp;its future smart home ecosystem,&nbsp;according to a post by TF International Securities analyst Ming-Chi Kuo.
What Happened: On Wednesday, Kuo posted on X that Apple is focusing on how users perceive and interact with robots, rather than their physical design. He emphasized that the tech giant is prioritizing sensing hardware and software as the core technologies for these potential products.
Apple did not immediately respond to <a href="http://pro.benzinga.com">Benzinga&#8217;s</a> request for comment.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Apple is exploring both humanoid and non-humanoid robots for its future smart home ecosystem, and these products are still in the early proof-of-concept (POC) stage internally. While the industry debates the merits of humanoid vs. non-humanoid designs, supply chain checks…
&mdash; 郭明錤 (Ming-Chi Kuo) (@mingchikuo) <a href="https://twitter.com/mingchikuo/status/1889694419907125342?ref_src=twsrc%5Etfw">February 12, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
However, Kuo cautioned that these products are still in the early proof-of-concept (POC) stage internally at Apple. He suggested that the timeline from POC to formal kick-off varies, and mass production of Apple&#8217;s robots likely won&#8217;t start until 2028 or later. The analyst also pointed out that the <a href="https://www.benzinga.com/news/24/10/41328193/apple-poured-1b-a-year-into-its-car-project-before-abandoning-it-tim-cooks-company-now-pulls-plug-on">Apple Car </a>remained stuck at the proof-of-concept stage and never moved forward.
SEE ALSO: <a href="https://www.benzinga.com/markets/25/02/43683976/apple-intelligence-rollout-in-china-and-europe-to-boost-iphone-sales-says-deepwaters-gene-munster">Apple Intelligence Rollout In China And Europe To Boost iPhone Sales, Says Deepwater&#8217;s Gene Munster</a>
Why It Matters:&nbsp;Apple is considering a range of robotic systems, from simple devices to complex humanoids, as part of a future smart home ecosystem. Last week, a blog on Apple's Machine Learning Research site revealed a robot in a video that resembled the Pixar lamp. The company is reportedly working on a smart home tabletop robot equipped with an iPad-like display and a robotic arm, suggesting Apple&#8217;s vision for AI-driven home automation.
The Tim Cook-led company&#8217;s venture into the robotics segment is <a href="https://www.benzinga.com/25/01/43325888/tesla-likely-to-sell-optimus-to-rival-companies-in-2026-price-point-of-humanoid-robot-to-be-detemined-by-demand-says-ceo-elon-musk">seen as a move to compete</a> with Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) and its humanoid robot, Optimus. In October, Elon Musk posted a video on X demonstrating Tesla&#8217;s Optimus robot successfully navigating uneven terrain.
The company has been unusually transparent about its robotics research, possibly to attract top talent in the field. Previously, Bloomberg columnist&nbsp;Mark Gurman&nbsp;revealed that the company has ramped up its recruitment efforts and published <a href="https://www.benzinga.com/media/25/02/43583398/top-analyst-says-apple-has-ramped-up-hiring-for-home-robotics-team">multiple job openings for robotics</a> specialists in recent weeks.
<ul>
<li>READ MORE: <a href="https://www.benzinga.com/etfs/specialty-etfs/25/02/43671778/why-the-mags-etf-has-remained-flat-year-to-date-despite-some-strong-performers">Why The MAGS ETF Has Remained Flat Year-to-Date Despite Some Strong Performers</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Tech

AAPL

TSLA

Apple's Next Big Bet? Tim Cook-Led Company Is 'Exploring' Humanoid As Well As Non-Humanoid Robots For Smart Home Future, Says Top Analyst

Contracts

NRGV

Energy Vault Announces Agreement For Delivery And Integration Of A 100 MW/200 MWh  Battery Energy Storage System At SEC Renewable Energy Park

LPTH

LightPath Technologies Acquires G5 Infrared; Aggregate Payable To G5 Members Is $27M

LightPath Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPTH#NASDAQ">LPTH</a>) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.04) by 75 percent. This is a 40 percent decrease over losses of $(0.05) per share from the same period last year. The company reported quarterly sales of $7.42 million which missed the analyst consensus estimate of $8.37 million by 11.24 percent. This is a 1.50 percent increase over sales of $7.32 million the same period last year.

LightPath Technologies Q2 EPS $(0.07) Misses $(0.04) Estimate, Sales $7.42M Miss $8.37M Estimate

The reason U.S. soft drinks primarily use high fructose corn syrup instead of sugar dates back to a trade barrier imposed by former President Ronald Reagan in the 1980s. This policy echoes in today&#8217;s trade landscape, where President Donald Trump&#8216;s tariffs continue to shape global policy.
What Happened: Reagan served as the 40th U.S. president between 1981 to 1989. During his tenure, he <a href="https://www.reaganlibrary.gov/archives/speech/proclamation-5294-import-quotas-certain-sugar-containing-articles">imposed</a> import quotas on sugar and sugar-containing articles to protect sugarcane farmers in the U.S.
This proclamation aimed to make imported sugar more expensive, or at least limit its availability, to artificially prop up the price of domestically produced sugar. This was a form of protectionism, designed to help American sugar farmers, even if it meant higher prices for consumers on products containing sugar.
It was after this announcement that Coca-Cola Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>) and PepsiCo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) shifted to high fructose corn syrup, according <a href="https://www.nytimes.com/1984/11/07/business/coke-pepsi-to-use-more-corn-syrup.html">to</a> the New York Times.
The report acknowledged the comments by the spokesperson of both beverage companies and said that using corn syrup would be less expensive than the traditional cane- or beet-based sweetener given the shrinking market of the sugar industry.
See Also: <a href="https://www.benzinga.com/news/earnings/25/02/43684201/cvs-health-forecasts-10-earnings-growth-for-2025-citing-aetnas-meaningful-recovery">CVS Health Forecasts 10% Earnings Growth For 2025, Citing Aetna&#8217;s &#8216;Meaningful Recovery&#8217;</a>
Why It Matters: While an import quota aims to limit the quantity of a good that can be imported into a country over a specific period, tariffs are another kind of trade barrier used by a country to tax imported goods. Both could lead to higher prices of goods domestically and create market distortions.
According to an old <a href="https://www.washingtonpost.com/archive/business/1982/05/09/reagans-quotas-on-sugar-grew-out-of-a-raw-deal/420f3f40-9144-45fd-93d2-c429ca1e6aab/">article </a>by the Washington Post dated May 8, 1982, Reagan&#8217;s decision to support domestic sugar prices, which led to the need for quotas, was a result of political dealmaking. He needed votes in Congress for his budget reconciliation bill and traded his opposition to sugar price support for those votes. 
David Stockman, Reagan&#8217;s budget director, was instrumental in this deal. Stockman reportedly acknowledged the policy&#8217;s flaws but prioritized securing votes.
In 2025, after Trump&#8217;s reelection, he threatened top U.S. trading partners Canada and Mexico with tariffs, which were delayed after some negotiations. However, he imposed a 25% tariff on steel and aluminum imports and a blanket 10% levy on imports from China.
In essence, while trade barriers like import quotas or tariffs could be used as a negotiating tool, they could be driven by political opportunism, undermine free trade principles, fuel prices, and damage international relations.
See Also: <a href="https://www.benzinga.com/general/market-summary/25/02/43683299/cisco-systems-lands-700m-ai-gold-rush-amid-increased-appetite-from-tech-giants-build-more-and-we-will-buy-more-customers-tell-ceo">Cisco Systems Lands $700M AI Gold Rush Amid Increased Appetite From Tech Giants: &#8216;Build More And We Will Buy More,&#8217; Customers Tell CEO</a>
What Do Experts Say: Higher import taxes can lead to increased costs for U.S. importers, potentially fueling domestic inflation, explained Subho Moulik, the founder and CEO of Appreciate. &#8220;A study by the Tax Foundation estimates that these tariffs could cost the average American household an extra $800 in 2025, pushing up inflation and squeezing consumer spending,&#8221; he added.
On the other hand, Craig Shapiro, a macro strategist at the Bear Traps Report, argues that tariffs are the "only way" to fund tax cuts without expanding the federal deficit.
Beyond rebalancing global trade and boosting American manufacturing, Shapiro posits that <a href="https://www.benzinga.com/25/02/43587245/tariffs-are-the-only-way-to-fund-tax-cuts-without-deficit-expansion-argues-expert-as-it-takes-center-stage-in-donald-trumps-economic-plan">tariffs could provide</a> a substantial revenue source for the U.S. government. He argues this income could be used to offset the cost of Trump&#8217;s proposed tax cuts and prevent further deficit growth.
Price Action: The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 and Nasdaq 100 indices, were mixed in premarket trading on Thursday. SPY fell 0.001% to $603.35, and QQQ was up 0.10% to $528.85, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43587245/tariffs-are-the-only-way-to-fund-tax-cuts-without-deficit-expansion-argues-expert-as-it-takes-center-stage-in-donald-trumps-economic-plan">Tariffs Are &#8216;The Only Way&#8217; To Fund Tax Cuts Without &#8216;Deficit Expansion&#8217;, Argues Expert As It Takes Center Stage In Donald Trump&#8217;s Economic Plan</a></li>
</ul>
Photo courtesy: Shutterstock

Government

Politics

Reagan's Sugar Quotas, Trump's Tariffs, And The Price Of Protectionism: Here's Why Coke And Pepsi In US Have High Fructose Corn Syrup Instead Of Sugar

IVAC

Trading Halt: Halt status updated at 8:25:00 AM ET: Quotation Resumption: News and Resumption Times

Leerink Partners analyst Mani Foroohar maintained a Hold rating on CureVac (CVAC – Research Report) on November 12. The company's shares closed yes...

Leerink Partners Sticks to Their Hold Rating for CureVac (CVAC)

Analyst Roy Buchanan of JMP Securities reiterated a Buy rating on CureVac (CVAC – Research Report), retaining the price target of $16.00. Roy Bucha...

CureVac: Strong Financial Position and Promising Pipeline Justify Buy Rating

California Gov. Newsom declares State of Emergency over bird flu

Vaccine stocks gain amid uptick in flu, COVID-19, RSV

Bird flu claims first U.S. life in Louisiana

Shares of Moderna (MRNA), one of a few drugmakers currently developing a vaccine for the H5N1 bird flu, were up nearly 10% in early trading after t...

Bird flu vaccine maker Moderna shares jump after first US death, Barron's says

Moderna, Novavax and other vaccine names extend gains amid COVID/flu concerns

Arbutus could benefit from Big Pharma bird flu vaccines: Jefferies

CureVac: Latest GBM Data Bodes Well For Next Program Check Point

Bird flu reaches NYC as live poultry markets shut down

ABUS

ARCT

BNTX

CSLLY

GLAXF

ROIV

Press Releases

CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma

CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business Update

CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress

CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza  mRNA Vaccine Program

CureVac's CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress

Events

CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

CureVac to Present at the 12th International mRNA Health Conference

CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer

CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update

JMP Securities

Leerink Partners

B of A Securities

SVB Securities

Comments

CureVac

매도 수량

CureVac (NASDAQ:CVAC) 주식, 공매도 수량 보고

뉴스

파트너 / 기고자

벤징가 글로벌